Patents by Inventor Pascal Barbry

Pascal Barbry has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of miR-199a-5p, targets and/or inhibitors thereof for the diagnosis, prognosis and treatment of fibroproliferative disorders
    Patent number: 10647984
    Abstract: The present invention relates to the use of the miRNA expression profile, particularly of miR-199a-5p, and the target genes regulated thereby for the diagnosis, prognosis and use of miR-199a-5p inhibitors for treating fibroproliferative disorders.
    Type: Grant
    Filed: January 3, 2017
    Date of Patent: May 12, 2020
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE LILLE
    Inventors: Nicolas Pottier, Bernard Mari, Brice Marcet, Pascal Barbry
  • USE OF miR-199a-5p, TARGETS AND/OR INHIBITORS THEREOF FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF FIBROPROLIFERATIVE DISORDERS
    Publication number: 20170183658
    Abstract: The present invention relates to the use of the miRNA expression profile, particularly of miR-199a-5p, and the target genes regulated thereby for the diagnosis, prognosis and use of miR-199a-5p inhibitors for treating fibroproliferative disorders.
    Type: Application
    Filed: January 3, 2017
    Publication date: June 29, 2017
    Inventors: Nicolas POTTIER, Bernard MARI, Brice MARCET, Pascal BARBRY
  • Compositions and methods for treating retrovirus infections
    Patent number: 9439923
    Abstract: The present invention relates to at least one nucleic acid (i) comprising or consisting of or (ii) encoding a nucleic acid comprising or consisting of, a sequence selected from the group consisting of: 1) SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 4, and 2) a sequence derived from SEQ ID NO: 1 to 4 by substitution deletion or insertion of at least one nucleotide, provided that a nucleic acid consisting of the sequence derived from SEQ ID NO: 1 to 4 is liable to induce HIV-1 expression in latent HIV-1-infected cells, for use as a medicament, in particular for treating retrovirus infections.
    Type: Grant
    Filed: November 26, 2009
    Date of Patent: September 13, 2016
    Assignee: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S)
    Inventors: Monsef Benkirane, Robinson Triboulet, Christine Chable-Bessia, Yamina Bennasser, Daniel Latreille, Oussama Meziane, Pascal Barbry, Bernard Mari, Jacques Reynes
  • Use of MicroRNA for treating diseases associated with a dysfunction of the cilia in multiciliated epithelial cells
    Patent number: 9023821
    Abstract: The present invention relates to a method for evaluating the regenerative and/or differentiation capacity of ciliated epithelial tissue in a vertebrate subject, in particular a mammal, preferably a human, and to the use of microRNA in treating illnesses associated with a dysfunction of multiciliated epithelial cells.
    Type: Grant
    Filed: July 26, 2010
    Date of Patent: May 5, 2015
    Assignee: Centre National de la Recherche Scientifique
    Inventors: Brice Marcet, Pascal Barbry, Rainer Waldmann, Bernard Mari, Christelle Coraux
  • USE OF miR-199a-5p, TARGETS AND/OR INHIBITORS THEREOF FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF FIBROPROLIFERATIVE DISORDERS
    Publication number: 20150045247
    Abstract: The present invention relates to the use of the miRNA expression profile, particularly of miR-199a-5p, and the target genes regulated thereby for the diagnosis, prognosis and use of miR-199a-5p inhibitors for treating fibroproliferative disorders.
    Type: Application
    Filed: February 6, 2013
    Publication date: February 12, 2015
    Inventors: Nicolas Pottier, Bernard Mari, Brice Marcet, Pascal Barbry
  • Use of MicroRNA for Treating Diseases Associated with a Dysfunction of the Cilia in Multiciliated Epithelial Cells
    Publication number: 20120184599
    Abstract: The present invention relates to a method for evaluating the regenerative and/or differentiation capacity of ciliated epithelial tissue in a vertebrate subject, in particular a mammal, preferably a human, and to the use of microRNA in treating illnesses associated with a dysfunction of multiciliated epithelial cells.
    Type: Application
    Filed: July 26, 2010
    Publication date: July 19, 2012
    Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Brice Marcet, Pascal Barbry, Rainer Waldmann, Bernard Mari, Christelle Coraux
  • COMPOSITIONS AND METHODS FOR TREATING RETROVIRUS INFECTIONS
    Publication number: 20120053223
    Abstract: The present invention relates to at least one nucleic acid (i) comprising or consisting of or (ii) encoding a nucleic acid comprising or consisting of, a sequence selected from the group consisting of: 1) SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 4, and 2) a sequence derived from SEQ ID NO: 1 to 4 by substitution deletion or insertion of at least one nucleotide, provided that a nucleic acid consisting of the sequence derived from SEQ ID NO: 1 to 4 is liable to induce HIV-1 expression in latent HIV-1-infected cells, for use as a medicament, in particular for treating retrovirus infections.
    Type: Application
    Filed: November 26, 2009
    Publication date: March 1, 2012
    Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S)
    Inventors: Monsef Benkirane, Robinson Triboulet, Christine Chable-Bessia, Yamina Bennasser, Daniel Latreille, Oussama Meziane, Pascal Barbry, Bernard Mari, Jacques Reynes